Learn More
PURPOSE Treatment options for patients with previously treated metastatic colorectal cancer (mCRC) are limited, and treatments with differing mechanisms of action are needed. PTK787/ZK 222584(More)
PURPOSE PTK787/ZK 222584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerability and promising activity in early-phase studies, which led to a phase III(More)
1513 Background: VEGF-mediated signaling through VEGF receptors is integral to GBM neovascularization and therefore an attractive therapeutic target. PTK/ZK is an oral, once-daily inhibitor of all(More)
1512 Background: VEGF-mediated signaling pathways may be critical to GBM neovascularization, and inhibition of VEGF pathways may be an important therapeutic target in GBM. PTK/ZK is a novel, oral(More)
3529 Background: PTK/ZK is an oral, antiangiogenic inhibitor of tyrosine kinase signaling of all known vascular endothelial growth factor receptors (VEGFR). PTK/ZK in combination with FOLFOX4 has(More)